Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: "Rosa Nadal" Clear advanced filters

  • 2017 saw the publication of clinical trial data and the approval of new treatment approaches for metastatic urothelial carcinoma. Pembrolizumab is now a well-established treatment for patients with disease progression after cisplatin, with high-level evidence supporting its superiority over second-line chemotherapy. For patients ineligible for cisplatin, atezolizumab and pembrolizumab provide meaningful clinical benefit as frontline therapies.

    • Joaquim Bellmunt
    • Rosa Nadal
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 15, P: 73-74

  • In this article, Nadal et al. review the pathological features, biology, clinical characteristics, and diagnostic challenges of SCC of the prostate, summarize the available treatment options, and highlight promising therapeutic strategies.

    • Rosa Nadal
    • Michael Schweizer
    • Mario A. Eisenberger
    Reviews
    Nature Reviews Urology
    Volume: 11, P: 213-219